ASH 2022 Conference Coverage
ASH 2022 Phase II Study of Myeloablative 8/8- or 7/8-Matched AlloSCT With Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil
By
ASH 2022 Conference Coverage
FEATURING
Alex Hoover
By
ASH 2022 Conference Coverage
FEATURING
Alex Hoover
Login to view comments.
Click here to Login
